• 제목/요약/키워드: Early mortality syndrome

검색결과 119건 처리시간 0.027초

장간막을 이용한 Boerhaave 증후군의 치료 (Surgical Treatment of Boerhaave Syndrome Using Mesentery)

  • 김형준
    • Journal of Chest Surgery
    • /
    • 제23권5호
    • /
    • pp.1040-1046
    • /
    • 1990
  • Despite the improved diagnostic and treatment modalities recently introduced for a variety of esophageal disorders, a perforation or leak from the esophagus remains a sources of morbidity and mortality regardless of the cause of leak. After the perforation of esophagus, the contamination of mediastinum and pleural cavity with food, bacteria and corrosive gastric juice leads to sepsis and cardiopulmonary dysfunction. The early diagnosis and early treatment are very important, and the delayed treatment leads to high risk of morbidity and mortality. We experienced one case of esophageal perforation, after forced vomiting in 48 years old male patient. We used omentum on the treatment of ruptured esophagus, and it was successfully managed.

  • PDF

신생아 호흡 장애 증후군에서 폐외공기누출의 임상적 고찰 (Pulmonary Air Leak in the Neonatal Respiratory Distress Syndrome)

  • 우석정
    • Journal of Chest Surgery
    • /
    • 제32권1호
    • /
    • pp.38-42
    • /
    • 1999
  • 1994년 9월에서 1997년 5월까지 신생아 호흡곤란을 보였던 환아들중 폐외 공기 누출을 나타내었던 48례를 대상으로 그 임상 양상을 분석하였는데 일차성 15례, 이차성 33례를 보였고, 순수 폐간질 기종이 19례, 다른 병변과 동반된 기흉이 19례 있었다. 정상 체중아가 많고 24시간내 증상 발현의 경우가 많았다. 폐 질환으로는 유리질 막증, 태변 흡입 증후군, 폐렴 등이 있었다. 25.2%의 원내 사망율을 보였고 유리질막증 환자에서 많았다.

  • PDF

Sepsis: Early Recognition and Optimized Treatment

  • Kim, Hwan Il;Park, Sunghoon
    • Tuberculosis and Respiratory Diseases
    • /
    • 제82권1호
    • /
    • pp.6-14
    • /
    • 2019
  • Sepsis is a life-threatening condition caused by infection and represents a substantial global health burden. Recent epidemiological studies showed that sepsis mortality rates have decreased, but that the incidence has continued to increase. Although a mortality benefit from early-goal directed therapy (EGDT) in patients with severe sepsis or septic shock was reported in 2001, three subsequent multicenter randomized studies showed no benefits of EGDT versus usual care. Nonetheless, the early administration of antibiotics and intravenous fluids is considered crucial for the treatment of sepsis. In 2016, new sepsis definitions (Sepsis-3) were issued, in which organ failure was emphasized and use of the terms "systemic inflammatory response syndrome" and "severe sepsis" was discouraged. However, early detection of sepsis with timely, appropriate interventions increases the likelihood of survival for patients with sepsis. Also, performance improvement programs have been associated with a significant increase in compliance with the sepsis bundles and a reduction in mortality. To improve sepsis management and reduce its burden, in 2017, the World Health Assembly and World Health Organization adopted a resolution that urged governments and healthcare workers to implement appropriate measures to address sepsis. Sepsis should be considered a medical emergency, and increasing the level of awareness of sepsis is essential.

Sepsis and Acute Respiratory Distress Syndrome: Recent Update

  • Kim, Won-Young;Hong, Sang-Bum
    • Tuberculosis and Respiratory Diseases
    • /
    • 제79권2호
    • /
    • pp.53-57
    • /
    • 2016
  • Severe sepsis or septic shock is characterized by an excessive inflammatory response to infectious pathogens. Acute respiratory distress syndrome (ARDS) is a devastating complication of severe sepsis, from which patients have high mortality. Advances in treatment modalities including lung protective ventilation, prone positioning, use of neuromuscular blockade, and extracorporeal membrane oxygenation, have improved the outcome over recent decades, nevertheless, the mortality rate still remains high. Timely treatment of underlying sepsis and early identification of patients at risk of ARDS can help to decrease its development. In addition, further studies are needed regarding pathogenesis and novel therapies in order to show promising future treatments of sepsis-induced ARDS.

신생아 호흡곤란증후군에서 인공 폐 표면활성제 조기요법의 중요성과 필요성 (The Importance and the Need of Early Pulmonary Surfactant Therapy in Premature Infant with Respiratory Distress Syndrome)

  • 김성미;윤혜선;김기수;배종우
    • Neonatal Medicine
    • /
    • 제16권2호
    • /
    • pp.101-109
    • /
    • 2009
  • Pulmonary surfactant (PS) therapy in premature infants has a remarkable impact on improving survival and outcomes in neonatal respiratory distress syndrome (RDS). Early PS therapy involves instillation of PS upon delivery of very premature infants or if there is evidence of RDS, such as an increased requirement of oxygen 2 hours after birth, especially in infants <30 weeks gestation. Early PS treatment in very premature infants results in a significant reduction in the severity of RDS, mortality, and incidence of pneumothorax, pulmonary interstitial emphysema, and bronchopulmonary dysplasia in comparison with late PS treatment. According to European and American consensus guidelines on the management of neonatal RDS, early PS instillation should be considered for infants <30 weeks gestation, infants with a birth weight <1,250 g, or if the mother has not received antepartum corticosteroids. We suggest that the Korean health insurance policy on RDS be modified so that PS can be used for better clinical outcomes of very premature infants.

Potential Immunotherapeutics for Immunosuppression in Sepsis

  • Shin, Jinwook;Jin, Mirim
    • Biomolecules & Therapeutics
    • /
    • 제25권6호
    • /
    • pp.569-577
    • /
    • 2017
  • Sepsis is a syndrome characterized by systemic inflammatory responses to a severe infection. Acute hyper-inflammatory reactions in the acute phase of sepsis have been considered as a primary reason for organ dysfunction and mortality, and advances in emergency intervention and improved intensive care management have reduced mortalities in the early phase. However it has been recognized that increased deaths in the late phase still maintain sepsis mortality high worldwide. Patients recovered from early severe illness are unable to control immune system with sepsis-induced immunosuppression such as immunological tolerance, exhaustion and apoptosis, which make them vulnerable to nosocomial and opportunistic infections ultimately leading to threat to life. Based on strategies to reverse immunosuppression, recent developments in sepsis therapy are focused on molecules having immune enhancing activities. These efforts are focused on defining and revising the immunocompromised status associated with long-term mortality.

외상환자의 초기 호흡 부전에 대한 흡입산화질소의 적용 (Therapeutic Role of Inhaled Nitric Oxide for Acute Respiratory Failure in the Early Phase of Trauma)

  • 김병성;경규혁;박호종
    • Journal of Trauma and Injury
    • /
    • 제28권3호
    • /
    • pp.104-107
    • /
    • 2015
  • Purpose: Nitric oxide (NO) is a vasodilator and inhaled NO (iNO) is used in acute respiratory distress syndrome (ARDS) to improve alveolocapillary gas exchange. The mechanism to improve oxygenation is likely to redistribute blood flow from unventilated areas to ventilated areas. Though improvement of oxygenation, iNO therapy has not been shown to improve mortality and considered as only rescue therapy in severe hypoxemia. We conducted the study to investigate an efficacy of iNO in trauma patients with severe hypoxemia. Methods: We reviewed the trauma patients who underwent iNO therapy retrospectively from 2010 to 2014. Degree of hypoxemia was represented as $PaO_2/FiO_2$ ratio (PFR) and the severity of patient was represented with sequential organ failure assessment (SOFA) score. Patients were divided into the survivor group and non-survivor group according to the 28-day mortality. Results: A total of 20 patients were enrolled. The mortality of 28-day was 40%. There were no significant differences between survivor and non-survivor group in age, sex, severity of injury, PFR and SOFA score. There was significant difference in initiation time of iNO after injury (p=0.047). Maximum combinations of sensitivity and specificity for timing of iNO therapy were observed using cut-off of 3-day after injury with a sensitivity of 88% and specificity of 75%. Conclusion: Though iNO therapy does not influence the mortality, iNO therapy may decrease the mortality caused by respiratory failure in the early phase of trauma.

  • PDF

침윤성 Streptococcus pneumoniae 감염에 의한 비전형적 용혈성 요독 증후군 1 례 (A Case of Atypical Hemolytic Uremic Syndrome Associated with Invasive Streptococcus pneumoniae Infection)

  • 황수자;유은선;이승주
    • Childhood Kidney Diseases
    • /
    • 제3권1호
    • /
    • pp.104-108
    • /
    • 1999
  • Atypical hemolytic uremic syndrome associated with neuraminidase-producing Streptococcus pneumoniae usually associated with invasive infection such as fulminant pneumonia, sepsis, and meningitis and may occur earlier in lift and has a higher mortality rate than typical hemolytic uremic syndrome. We have experienced a 22-month-old female patient with hemolytic uremic syndrome associated with S. pneumoniae pneumonia and empyema. The patient was treated with ceftriaxone and washed red blood cell transfusion. As the disese course could be aggravated by the use of blood products containing anti-Tomsen-Friedenreich antigen, early recognition and sensible use of blood products such as washed RBC might lead to the improved outcome.

  • PDF

St. Jude medical valve의 임상적 연구;조기 사망의 술전 위험인자와 술후 합병증에 대한 고찰 (Clinical Analysis of St. Jude Medical Valve Replacement - Clinical Analysis of Risk Factors for Early Death and Valve-related Complication -)

  • 이언재
    • Journal of Chest Surgery
    • /
    • 제24권1호
    • /
    • pp.26-35
    • /
    • 1991
  • From January 1984 to June 1990, 188 patients have undergone cardiac valve replacement [114 MVR, 27 AVR, 47 Multiple valve replacement] with the St. Jude Medical prosthesis. The early mortality rate was 6.9%. The most common cause of early death was low output syndrome. There were no cases of valve-related early death. The risk factors for early death were advanced preoperative NYHA functional class [> IV], and prolonged ECC and ACC time. The 175 early survivors were followed-up for a total 372.7 patient-year over a period of 2 to 74 months [Mean $\pm$SD: 25.6$\pm$18.6 months]. During follow up, 12 patient died and late mortality rate was 6.9%. There were three valve-related late deaths: two were due to valve thrombosis and one was due to hemorrhage. Most late deaths [58%, 7/12] were from cardiac non-valvular causes. Valve-related complications occurred at a linearlized rate of 3.5% /pt-yr. Embolism occurred at a rate of 0.8% /pt-yr. There were three cases of valve thrombosis [0.8% /pt-yr: two fatal]. Hemorrhage due to anticoagulant occurred in 5 patients and a rate of 1.3% pt-yr [one fatal]. Five-year actuarial survival rate was 86.5 $\pm$5.1% and 97% of patient were in NYHA functional class I or II at three months postoperatively.

  • PDF

급성 심근경색에 합병된 심실중격 결손증의 수술적 치료: 1례 보고 (Surgical Management of Post-AMI VSD - A Case Report -)

  • 황석하
    • Journal of Chest Surgery
    • /
    • 제25권4호
    • /
    • pp.424-428
    • /
    • 1992
  • Post-AMI VSD is an infrequent but often catastrophic complication of acute myocardial infarction In general, the mortality is associated with end organ failure due to low output syndrome. Therefore, a stable hemodynamic is necessary to prevent the end organ failure. If a supportive therapy does not accomplish it, surgical intervention should be considered. Recently, we have experinced a case of post-AMI VSD with cardiogenic shock. Early recognition and surgical repair of post-AMI VSD gave us a good result. Postoperative result was satisfactory and recovery was uneventful. We believe that early surgical repair can be lifesaving in the case of post-AMI VSD with cardiogenic shock.

  • PDF